AbbVie’s Skyrizi sustains clinical and endoscopic outcomes in ulcerative colitis for up to three years
ABBV•AbbVie said Skyrizi maintained clinical and endoscopic improvements in ulcerative colitis for up to three years, while Rinvoq sustained Crohn’s disease outcomes for approximately four years. The company will present 20 inflammatory bowel disease research abstracts at UEG Week in Barcelona from Oct. 17-20, 2026.
1. Research presentations
AbbVie will present 20 inflammatory bowel disease research abstracts at UEG Week. The findings include sustained Skyrizi outcomes in ulcerative colitis for up to three years and Rinvoq outcomes in Crohn’s disease for approximately four years; other presentations will cover real-world treatment switching, subcutaneous Skyrizi in Crohn’s disease, and investigational therapy ABBV-466.
